Bioinformatics Analysis of BIRC5 in Human Cancers

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2022 Sep 16

PMID 36111008

Authors

Han-Bin Ye

Bao-Jun Ma

Gao-Qiang Meng

Shuo Tao

Yong Wang

Zhenghua Chen

Wei Zhao

Bing-Yan Ren

Zi Ye

Affiliations

Soon will be listed here.

Abstract

Background: An inhibitor of apoptosis (IAP) family member, baculoviral IAP repeat containing five (BIRC5) plays an important role in the occurrence and development of tumors. However, the underlying mechanism in human cancers remains unclear.

Methods: In this study, we investigated BIRC5 expression and explored the prognostic value of BIRC5 in different human cancers via bioinformatics analysis, including the databases of Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN, GEPIA, DriverDBv3, GeneMANIA, WEB-based Gene Set Analysis Tool (WebGestalt) and TIMER.

Results: In most human cancers, BIRC5 usually had higher expression compared to normal human tissues. High expression of BIRC5 could increase the mortality of patients with adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD) (P<0.05). Cox analysis demonstrated that high BIRC5 expression was an independent factor for poor overall survival (OS) [hazard ratio, (HR) >1, P<0.05]. There were differences in BIRC5 expression in the case of TP53 mutation, different tumor grades, and stages. Interactive genes for BIRC5 mainly participated in apoptosis, cell division, cell cycle, and cancer pathways, strongly suggesting its oncogenic role in promoting cancer cell proliferation and cancer development. In addition, BIRC5 expression exhibited a close correlation with immune infiltration, which was related to the cumulative survival rate, especially in LGG. The elevated expression of BIRC5 could be regulated through TP53 mutation, tumor stage, and tumor grade (P<0.05).

Conclusions: As a result of our findings, BIRC5 appears to be an independent unfavourable prognostic biomarker in human cancers. BIRC5 may become a potential clinical target in the future for the treatment of cancers.

Citing Articles

Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus.

Zhu M, Chu Y, Yuan Q, Li J, Chen S, Li L Front Bioinform. 2025; 5:1495052.

PMID: 39944135 PMC: 11810980. DOI: 10.3389/fbinf.2025.1495052.

BIRC5 as a prognostic and diagnostic biomarker in pan-cancer: an integrated analysis of expression, immune subtypes, and functional networks.

Li G, Wang Y, Wang W, Lv G, Li X, Wang J Front Genet. 2024; 15:1509342.

PMID: 39703228 PMC: 11655497. DOI: 10.3389/fgene.2024.1509342.

BIRC5 knockdown ameliorates hepatocellular carcinoma progression via regulating PPARγ pathway and cuproptosis.

Mai Y, Ji Z, Tan Y, Feng L, Qin J Discov Oncol. 2024; 15(1):706.

PMID: 39585552 PMC: 11589110. DOI: 10.1007/s12672-024-01592-y.

Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis.

Yin M, Wang Y, Ren X, Han M, Li S, Liang R Front Endocrinol (Lausanne). 2023; 14:1250033.

PMID: 38053725 PMC: 10694291. DOI: 10.3389/fendo.2023.1250033.

BIRC5 Inhibition Is Associated with Pyroptotic Cell Death via Caspase3-GSDME Pathway in Lung Adenocarcinoma Cells.

Zhang Q, Chen X, Hu Y, Zhou T, Du M, Xu R Int J Mol Sci. 2023; 24(19).

PMID: 37834111 PMC: 10572361. DOI: 10.3390/ijms241914663.

References

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Wang J, Duncan D, Shi Z, Zhang B . WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res. 2013; 41(Web Server issue):W77-83. PMC: 3692109. DOI: 10.1093/nar/gkt439. View

Lindner A, Lucantoni F, Vareslija D, Resler A, Murphy B, Gallagher W . Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. J Mol Med (Berl). 2018; 96(10):1025-1037. DOI: 10.1007/s00109-018-1675-0. View

Li C, Qin F, Hong H, Tang H, Jiang X, Yang S . Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis. PeerJ. 2019; 7:e7619. PMC: 6733258. DOI: 10.7717/peerj.7619. View

Wang X, Simpson E, Brown K . p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis. Cancer Res. 2015; 75(23):5001-7. DOI: 10.1158/0008-5472.CAN-15-0563. View

Troiano G, Guida A, Aquino G, Botti G, Losito N, Papagerakis S . Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma. Int J Mol Sci. 2018; 19(9). PMC: 6174346. DOI: 10.3390/ijms19092664. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Di Agostino S, Fontemaggi G, Strano S, Blandino G, DOrazi G . Targeting mutant p53 in cancer: the latest insights. J Exp Clin Cancer Res. 2019; 38(1):290. PMC: 6612074. DOI: 10.1186/s13046-019-1302-0. View

Liu S, Shen P, Chen C, Hsu A, Cho Y, Lai Y . DriverDBv3: a multi-omics database for cancer driver gene research. Nucleic Acids Res. 2019; 48(D1):D863-D870. PMC: 7145679. DOI: 10.1093/nar/gkz964. View

10.

Zhang H, Li W, Gu W, Yan Y, Yao X, Zheng J . MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5. Cell Prolif. 2019; 52(5):e12640. PMC: 6797509. DOI: 10.1111/cpr.12640. View

11.

Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C . Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch. 2006; 449(2):164-70. DOI: 10.1007/s00428-006-0239-9. View

12.

Sun P, Jin Y, Kim H, Seo A, Jheon S, Lee C . Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Arch. 2013; 463(3):427-36. DOI: 10.1007/s00428-013-1462-9. View

13.

Solanki S, Chakinala R, Haq K, Khan M, Kifayat A, Linder K . Inpatient burden of gastric cancer in the United States. Ann Transl Med. 2020; 7(23):772. PMC: 6990011. DOI: 10.21037/atm.2019.11.54. View

14.

Lamkanfi M, Kanneganti T . Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2009; 42(1):21-4. PMC: 2787741. DOI: 10.1016/j.biocel.2009.09.013. View

15.

Krafft U, Tschirdewahn S, Hess J, Harke N, Hadaschik B, Olah C . Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urol Oncol. 2019; 37(11):810.e7-810.e15. DOI: 10.1016/j.urolonc.2019.04.015. View

16.

Sbiera S, Kroiss M, Thamm T, Beyer M, Majidi F, Kuehner D . Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential. Horm Metab Res. 2012; 45(2):137-46. DOI: 10.1055/s-0032-1327750. View

17.

Unruhe B, Schroder E, Wunsch D, Knauer S . An Old Flame Never Dies: Survivin in Cancer and Cellular Senescence. Gerontology. 2015; 62(2):173-81. DOI: 10.1159/000432398. View

18.

Shalapour S, Lin X, Bastian I, Brain J, Burt A, Aksenov A . Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017; 551(7680):340-345. PMC: 5884449. DOI: 10.1038/nature24302. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Duffy M, ODonovan N, Brennan D, Gallagher W, Ryan B . Survivin: a promising tumor biomarker. Cancer Lett. 2007; 249(1):49-60. DOI: 10.1016/j.canlet.2006.12.020. View